Study details
Enrolling now
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
NCT IDNCT06113302ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
40
Study length
about 2.3 years
Ages
18+
Locations
1 site in TX
What this study is about
This trial is testing luspatercept in people with lower risk myelodysplastic syndromes. It aims to see if luspatercept helps reduce the need for blood transfusions and how it affects blood cell counts.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Luspatercept
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
luspatercept
Endpoints
Primary: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0